The U.S. Food and Drug Administration approved a long delayed migraine drug made by GlaxoSmithKline and Pozen.
The drugmakers said Wednesday that the FDA approved Treximet for the acute treatment of migraine attacks. Treximet is a combination of an anti-inflammatory drug and Glaxo's Imitrex, which is expected to begin competing against generics this year.
The FDA had twice asked the companies for more data on Treximet since they first submitted it for approval in 2005.
Glaxo is also seeking regulatory approval for modified versions of another two products that, like Imitrex, are facing the loss of patent protection _ Lamictal for epilepsy and Requip for Parkinson's disease and restless-leg syndrome.
Glaxo shares rose 0.5 percent to 1,076 pence ($21.19).